Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 26, 2020
Daily News
February 26, 2020
- MHLW Orders Label Revisions for 9 Hep C Drugs
February 26, 2020
- Drug Makers in Japan Upping Coronavirus Measures; Takeda Switches to Online Interviews for New R&D Hires
February 26, 2020
- Japan Plans to Reimburse Coronavirus Tests: Health Minister
February 26, 2020
- Takeda’s ALK Drug Alunbrig Gets FDA’s Priority Status for Frontline NSCLC
February 26, 2020
- Shionogi’s Antibiotic Fetroja Now Available in US
February 26, 2020
- Japan Adopts Basic Plan against Novel Coronavirus
February 26, 2020
- Kissei Takes Over Distribution of Desmopressin Brands from Ferring in Japan
February 26, 2020
- Eisai Obtains China Rights for Fuji Yakuhin's Gout Treatment Dotinurad
February 26, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…